May 3, 2019 10:41 AM EDT

Microcap biotech VistaGen turned to pennystock after PhII results show its depression drug doesn't work solo

Amber Tong

VistaGen Therapeutics’ AV-101 has flunked an exploratory Phase II, quashing hopes that the drug could work as a monotherapy for treatment-resistant depression.

To be sure …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Microcap biotech VistaGen turned to pennystock after PhII results show its depression drug doesn't work solo

Amber Tong

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Lower attendance at cell and gene therapy conference mirrors challenged industry

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

HHS can require approval for drugmakers to apply 340B rebate models, court rules

Mi­cro­cap biotech Vista­Gen turned to pen­ny­s­tock af­ter PhII re­sults show its de­pres­sion drug does­n't work so­lo

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Microcap biotech VistaGen turned to pennystock after PhII results show its depression drug doesn't work solo